Elevance Health's ELV Shares Plummet 3.41% on $1.43 Billion Volume Ranking 93rd as CMS Sanctions and Legal Probe Weigh on Investor Confidence

Market Snapshot

Elevance Health (ELV) shares declined 3.41% on March 3, 2026, with a trading volume of $1.43 billion, ranking 93rd in market activity. The stock’s performance reflects heightened investor caution following recent disclosures and regulatory developments.

Key Drivers

The sharp drop in Elevance’s stock price is primarily attributed to the Centers for Medicare & Medicaid Services (CMS) imposing intermediate sanctions on the company’s Medicare Advantage-Prescription Drug plans. On February 27, 2026, Elevance disclosed via a Form 8-K that CMS notified it of its intent to suspend enrollment and certain communications with Medicare beneficiaries, effective March 31, 2026. The sanctions stem from Elevance’s alleged noncompliance with risk adjustment data submission requirements, including the use of flash drives instead of CMS-approved electronic systems for submitting diagnosis codes over the past seven years. CMS cited “substantial and persistent” noncompliance, which could disrupt revenue streams tied to Medicare Advantage (MA) enrollment and weaken the company’s market position.

Compounding the regulatory pressure, Johnson Fistel, PLLP, a shareholder-rights law firm, announced an investigation into Elevance and its executives for potential violations of federal securities laws. The firm is examining whether the company adequately disclosed risks related to its compliance practices and the financial implications of the CMS sanctions. Such investigations often erode investor confidence, as they highlight governance risks and potential legal liabilities. Elevance’s stock has already faced downward pressure, with analysts noting that the firm’s market share in MA could shrink if enrollment restrictions persist.

The CMS sanctions also raise broader financial concerns. Elevance’s MA segment is a critical revenue driver, and the suspension of enrollment could accelerate member attrition. While the company reported a 14% membership decline in 2026 through strategic exits from unprofitable markets, the new sanctions threaten to exacerbate losses. Analysts at Leerink estimate that reputational damage from regulatory scrutiny could further deter brokers and agents from promoting Elevance’s plans, complicating future growth. Additionally, the company faces potential clawbacks for overpayments tied to unsupported diagnosis codes, which could strain cash flow.

Elevance’s response to the crisis has been mixed. The firm stated it is working with CMS to address concerns, emphasizing that it revised its data submission practices in April 2023 following regulatory guidance. However, CMS noted ongoing noncompliance as recently as October 2025, casting doubt on the effectiveness of these changes. The firm also requested that CMS waive clawbacks for unsupported diagnosis codes—a move the regulator deemed contrary to federal rules. This tension underscores the regulatory challenges Elevance faces in maintaining its MA operations, with the judge’s decision on whether to allow the sanctions to take effect scheduled for March 31, 2026.

The stock’s decline also reflects broader market sentiment. While Elevance’s CarelonRx and Carelon Services segments remain relatively stable, the healthcare sector is under scrutiny for risk adjustment practices. The Biden administration’s reforms to MA risk scoring have already pressured insurers like UnitedHealth Group, and the Trump administration’s proposed safeguards suggest a continued regulatory focus. Elevance’s struggles highlight the fragility of MA business models reliant on accurate data reporting, with investors increasingly wary of compliance risks.

In summary, Elevance’s stock performance is driven by a confluence of regulatory penalties, legal investigations, and operational vulnerabilities. The CMS sanctions and securities probe have directly impacted investor confidence, while long-term concerns about MA profitability and governance practices persist. The company’s ability to resolve these issues before March 31 will likely determine the trajectory of its stock, with further declines possible if the sanctions are enforced or legal proceedings escalate.